The Review Group / NCI Cancer Prevention Program Review Group / Scientific / Acknowledgments Executive Summary More / /
Country
United States / /
Event
FDA Phase / /
Facility
National Cancer Institute / /
IndustryTerm
throughput technologies / Cancer Prevention / in vivo animal systems / energy consumption / treatment of already diagnosed disease / assay systems / Human Cancer Prevention / animal model systems / tobacco products / Cancer Prevention Program / established treatment trials groups / prevention of human cancers / exogenous and endogenous chemicals / /
MedicalCondition
Cancers / III cancer / already diagnosed disease / Cancer / disease / intramural cancer / human cancer / human cancers / human carcinogenesis / prostate and other cancers / clinically overt cancers / certain cancers / lung cancer / cancer-associated infections / skin cancers / breast cancer / comprehensive cancer / restructured cancer / multimodality cancer / /
MedicalTreatment
Chemoprevention / Oncology Therapy / /
Organization
Chemoprevention Trials Methodological Considerations Cancer Prevention Trials Group Prevention Trials Committee for Biological Studies Recommendations Behavioral Research and Behavioral Interventions Trials / National Cancer Institute / Congress / National Institute of Health / Prevention Research Organization / Food and Drug Administration / BSA subcommittee / Prevention Division / Board of Scientific / Division of Cancer Prevention / Cancer Prevention Program and Budget Intramural Component Organization / NCI Prevention Division / Division of Cancer Prevention and Control Inclusion of Prevention and Control Research / National Cancer Advisory Board / Division of Extramural Activities Report / NCI Board of Scientific / NCI Organization / /
Position
Advisors / Director and the Chair / physician / /
Product
NCI / /
PublishedMedium
Extrapolation / /
Technology
radiation / drug discovery / high throughput technologies / drug development / /
NCIDEA: Cancer Prevention Program Review Group